Andrew Maleki leads corporate development at Lassen Therapeutics. Mr. Maleki has over a decade of experience in the biotech industry across strategy, business development, and operational roles and has played a key role in raising >$500M in capital as well as licensing and M&A deals with an aggregate value over $5 billion.
Prior to Lassen, Mr. Maleki was in positions of increasing responsibility at Jazz Pharmaceuticals, where he was responsible for leading collaborations, licensing transactions, and mergers and acquisitions across a variety of therapeutic areas. Earlier in his career, he worked at PureTech Health and ClearView Healthcare Partners across operational, business development, and strategy roles.
Mr. Maleki holds an MBA from Harvard Business School and a B.A. in Biology and Economics with distinction from Yale University.